Our findings, however, demonstrated that higher levels of SPARC expression in the primary CRC was associated with a good disease outcome and a better long-term cancer-free survival >60 months in both stage II and III CRC, and conversely that lower SPARC expression was associated with a more advanced clinical disease stage. Here, SPARC is linked to colorectal carcinoma.